clinical trial | Q30612 |
P3098 | ClinicalTrials.gov ID | NCT03564678 |
P6099 | clinical trial phase | phase II clinical trial | Q42824440 |
P17 | country | United States of America | Q30 |
P582 | end time | 2020-12-01 | |
P921 | main subject | vitamin B | Q183206 |
P1050 | medical condition | leukemia | Q29496 |
P2899 | minimum age | 12 | |
P1132 | number of participants | 78 | |
P4844 | research intervention | folic acid | Q127060 |
vitamin B | Q183206 | ||
asparaginase | Q421534 | ||
inotuzumab ozogamicin | Q3799041 | ||
pegaspargase | Q7160547 | ||
P859 | sponsor | The University of Texas MD Anderson Cancer Center | Q1525831 |
P580 | start time | 2018-05-17 | |
P8363 | study type | interventional study | Q78089383 |
P1476 | title | Mitochondrial Cofactors for the Treatment of Hyperbilirubinemia Due to PEG-asparaginase and or Inotuzumab Ozogamicin in Patients With Acute Lymphoblastic Leukemia (ALL) |
Search more.